Biography for Damian Garde
Damian is an editor with Fierce's life sciences publications, writing for FierceBiotech, FierceMedicalDevices and FierceCRO. Prior to joining Fierce, he worked for Patch.com in Maryland, and The Albuquerque Journal and Weekly Alibi in Albuquerque, NM. Damian lives in Washington, DC, and considers himself the foremost Carmelo Anthony apologist in the greater metropolitan area. You can email him at email@example.com and follow @DamianFierce on Twitter.
Articles by Damian Garde
Diagnostics giant LabCorp is betting sluggish demand and uncertain reimbursement will step all over its 2014 revenue, an announcement that sent the company's shares down nearly 10% in premarket trading.
Edwards Lifesciences' days of market dominance are numbered, and with Medtronic impending on its U.S. monopoly and Boston Scientific soon to enter the crowded European space, the California devicemaker is less than optimistic about 2014 sales.
Albany, NY, device outfit AngioDynamics is planning to consolidate two of its plants, shedding up to 100 employees in an effort to save as much as $18 million over the next three years.
Amid scorn and scrutiny from the FDA, 23andMe is facing a class-action lawsuit claiming the company misled customers in selling genetic tests with no real scientific value, and plaintiffs want at least $5 million in damages.
Volcano has approved a $200 million stock repurchase plan, a sign the company is listening to an activist investor that wants it to boost its share value and find itself a buyer.
23andMe has stopped advertising its personal genetic test after a strongly worded rebuke from the FDA, Reuters reports, but the company is still selling its $99 kit despite the agency's demands.
HeartWare has bought out CircuLite for as much as $350 million, acquiring a cardiac assist device for less-severe patients and broadening its offerings in the heart failure world.
Now that the FDA has fired off a strongly worded rebuke of its Personal Genome Service, 23andMe is standing by the accuracy of its un-approved test, promising to work with regulators but giving no indication that it'll stop selling its sole product.
Cardiovascular Systems hauled in a gross $102 million in a stock offering, cash that'll help the company hit the ground running with its recently approved atherectomy device.
Italian device magnate Sorin is expecting its of-late focus on new products to pay off down the line, forecasting double-digit annual sales growth in the next 5 years.